These data suggest that AM and TRPV2 correlated expression may contribute to creating ideal conditions for metastatic spread in patients with prostate or bladder cancer and could constitute a prospective prognostic marker and a potential therapeutic target to increase the life expectancy of the patients. The gene discussed is TRPV2; the disease is urinary bladder cancer.